Largest review to date of ivermectin use in cancer patients finds no safety concerns, promising anecdotal reports, and strong preclinical evidence of tumor suppression.
The study titled “A Review of Ivermectin Use in Cancer Patients: Is it Time to Repurpose the Ivermectin in Cancer Treatment?” was just published in the journal Acta Poloniae Pharmaceutica – Drug Research
This systematic review aimed to evaluate the potential for repurposing ivermectin as an anticancer agent, through a dual focus on:
- The clinical safety of ivermectin in cancer patients, based on case reports and series involving its use for parasitic infections
- The preclinical antitumor activity of ivermectin, drawn from laboratory and animal studies
A total of 2,273 publications were identified, of which 26 studies met inclusion criteria. These studies involved 36 cancer patients who had received oral ivermectin, primarily for parasitic infections.
While none of the patient cases were designed to evaluate antitumor effects, the review also summarizes a growing body of preclinical evidence supporting ivermectin’s potential anticancer mechanisms.
The post Ivermectin Shows Striking Anticancer Potential and Remarkable Safety appeared first on Easton Spectator.
Click this link for the original source of this article.
Author: Easton Spectator
This content is courtesy of, and owned and copyrighted by, https://www.eastonspectator.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
